Avidity Biosciences (NASDAQ:RNA) has surged ~16% Wednesday, reaching an all-time high of $56.00 earlier in the trading ...

Keay Nakae’s rating is based on Avidity Biosciences’ strategic focus on genetically validated targets for cardiomyopathies using their proprietary antibody oligonucleotide conjugate (AOC) technology.

Barclays analyst Gena Wang maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $63.00.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Avidity Biosciences Inc. has announced two new precision cardiology development candidates targeting rare genetic cardiomyopathies. AOC-1086 targets phospholamban (PLN) cardiomyopathy and AOC-1072 ...

SAN DIEGO, Oct. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...

Avidity Biosciences (NASDAQ ... Avidity is best known for developing antibody oligonucleotide conjugates (AOC) therapeutics, primarily for muscular dystrophy conditions. Its latest stage candidate ...

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide ...

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide ...